Citation:Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al 2012

From Cancer Guidelines Wiki

Citation


Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2012 Nov;62(5):745-52 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22704366.


This is a publication of ERSPC

Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Tracy Tsangcompleted
For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?Suzanne Hughescompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. ERSPC
  2. Introduction
  3. PSA Testing strategies